Superiority of upadacitinib over placebo as induction therapy for patients with moderately to severely active ulcerative colitis was observed.
Since the first anaphylactic reactions after injection of the COVID-19 vaccines, studies on side effects and severe allergic events have been ongoing worldwide. Now there are also first results on a successful premedication scheme and vaccination concepts for high-risk patients.
Eight COVID-19 vaccines are licensed in the Philippines. Severe reactions to these and anaphylactic events occur very rarely. But to react early, an interdisciplinary team set up a concept for different risk groups.
The number of allergic reactions requiring treatment has risen sharply in recent years. Among triggering medications, antibiotics play a major role in daily practice. Yet, there is still a need for better documentation.
Food allergies are rising but it is still unclear why. This is also reflected in guidelines for the prevention and treatment of food allergies. Risk factors are being discussed again.
CRSwNP usually accompanies those affected throughout their lives. Multiple surgeries and long-term steroid therapy are the standard treatment. This can be extended by biologics use.
Clear or almost clear skin and mild or no itch symptoms were top predictors of maintained response to tralokinumab in moderate-to-severe AD.
A British study showed that both a direct-to-consumer app and an app used for scientific purposes failed to recognise rare skin cancers.
Ligelizumab for adolescents with chronic spontaneous urticaria, insufficiently controlled with antihistamines, did not raise new safety concerns.
In different skin models, key receptors could be identified whose modulation can help in creating compromised-skin topicals against SARS-CoV-2 entry.
According to studies, more than two-thirds of schoolchildren have headaches on a regular basis. Around 20% of children and adolescents repeatedly miss lessons as a result.
The assessment of a novel anti-OX40 antibody resulted in substantial reductions in Eczema Area and Severity Index scores in a recent trial.
A study published in JAMA investigated whether adding antithrombotic therapy to placebo reduced major cardiopulmonary complications over a 45-day treatment period in COVID-19 outpatients.
For atopic dermatitis with less than 10% body surface area involvement, difelikefalin has exhibited significant efficacy in itch reduction.
A study linked genital warts and human leukocyte antigen systems. Protective and risk alleles could be identified as future antiviral or vaccine targets.
A dose-ranging study showed that oral treatment with the JAK3 inhibitor ritlecitinib is efficacious in reducing depigmented areas in the face.
A elderly-focused subanalysis of phase 3 trials revealed IGA-TS in 60.5% of atopic dermatitis patients applying 1.5% ruxolitinib cream over 8 weeks.
What influence do cardiological, social or neurological problems have on psychiatric diseases and vice versa? This question was addressed by the speakers at the symposium "Recognising and treating psychiatric comorbidities".
A trial showed abrocitinib superiority over dupilumab in fast itch control and skin clearance in adult patients with moderate-to-severe atopic dermatitis.
A long-term assessment of topical tapinarof found a high rate of complete disease clearance as well as a lasting response up to 52 weeks.